A retrospective study using data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset looked at the efficacy of nivolumab (225 patients) and cabozantinib (53 patients) when used to treat metastatic renal cell carcinoma (RCC) in the real world.

The study found similar outcomes for patients treated with nivolumab and cabozantinib in the second-line, suggesting that both are acceptable options for patients whose cancer progresses following first-line treatment with vascular endothelial growth factor receptor (VEGFR)-targeted therapy, such as sunitinib or pazopanib.

Read more in Current Oncology here